MARY HORSEMAN: Open Payments
NPI 1598778680 · EASTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 40 payments from 14 companies in 2025. Trend: 2023 $467 · 2024 $1,085 · 2025 $900
Food & beverage: $900
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $187 |
| ABBVIE INC. | 5 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| PFIZER INC. | 4 | $68 |
| Intercept Pharmaceuticals, Inc. | 3 | $68 |
| GENZYME CORPORATION | 2 | $60 |
| Gilead Sciences, Inc. | 2 | $44 |
| QOL Medical, LLC | 2 | $43 |
| Celltrion USA Inc. | 2 | $39 |
Products named: TREMFYA, XIFAXAN, VELSIPITY, OCALIVA, CREON, DUPIXENT, ENTYVIO, Sucraid.
Industry payments across MD — which companies pay providers there.
